Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma.
Bruno SangroPeter R GalleRobin Kate KelleyChaiyut CharoentumEnrico N De ToniYurii OstapenkoJeong HeoAnn-Lii ChengAndrea Wilson WoodsCharu GuptaJayne AbrahamCarrie L McCoyNikunj PatelAlejandra NegroArndt VogelGhassan K Abou-AlfaPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Compared with sorafenib, STRIDE and durvalumab were associated with clinically meaningful, patient-centered GHS/QoL, functioning, and symptom benefits in people with uHCC. These findings support the benefits of the STRIDE regimen compared with sorafenib for a diverse population reflective of the global uHCC population.